Skip to main content
. 2024 Nov 18;74(2):223–233. doi: 10.2337/db24-0340

Table 3.

Association of genotypic risk scores with AAD

Trait Chr Start (HG38) End (HG38) Type Effect P
Methylation* (probe location in HG38)
 cg17270013 (Chr15:78,944,497) 15 78,185,519 79,036,756 cis −0.10 4.61E-06
 cg07448499 (Chr15:78,944,815) 15 78,185,519 79,036,756 cis −0.08 5.62E-05
 cg17922215 (Chr15:78,944,803) 15 78,388,660 79,012,268 cis −0.08 9.20E-05
 cg20059407 (Chr15: 78,941,976) 15 78,796,769 78,965,955 cis −0.07 3.99E-04
 cg25744700 (Chr15:78,944,875) 15 77,955,110 79,019,093 cis −0.07 6.89E-04
Expression
 Whole blood (eQTLGen) 15 77,974,313 79,068,033 cis −0.08 2.93E-04
Protein levels
 Pro-cathepsin H 6 31,483,699 33,225,090 trans −2.01 4.44E-05
 Pro-cathepsin H 15 67,936,125 88,137,453 cis −0.07 6.41E-03

*Methylation probes on HumanMethylation450 and EPIC arrays corresponding to CpG island in CTSH locus: Chr15:78944698–78945229.

†RNA sequencing and arrays meta-analysis for eQTLGen.

‡Pro-cathepsin H protein levels measured in plasma with SomaScan version 3.